We are an AI company with end-to-end capability from early drug discovery to late-stage clinical development. Med block combines the power of computational medicine and advanced AI with the principles of open systems and cloud computing to transform the way medicines are designed, developed, tested and brought to market.
The Benevolent Platform is designed to power target identification so we can find new ways to treat a disease, molecular design so we can develop the most effective medicines, and clinical mechanistic stratification so we can understand how individual patients will respond to treatment. We combine all three to generate new insights into the underlying causes of disease, as well as routes to new or more effective treatments.
Our approach has brought together experts from technology, research and scientific domains to work side by side on better, faster ways to develop new medicines. This diversity, combined with our expertise and open working practices, creates an optimum environment for innovation and scientific breakthrough.